A multicenter retrospective study of treating advanced NSCLC patients (PD-L1 tumor proportion score ≥ 50%) with pembrolizumab also indicated that there was no correlation between bone metastasis and PFS [100], which was opposite to another multicenter study in which the same type of patients was treated with the same ICI [105]. This evidence concerns the gene CD274 and neoplasm.